NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Neogen Corporation (NASDAQ: NEOG). Shareholders who purchased shares of NEOG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/neogen-corporation-loss-submission-form/?id=163679&from=3 CLASS PERIOD: January ...

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's lead cell therapy candidate, deramiocel, and its FDA approval process [1][2]. Group 1: Allegations and Impact - Shareholders who purchased shares of Capricor during the class period from October 9, 2024, to July 10, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [1]. - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential FDA approval while concealing adverse facts from its Phase 2 HOPE-2 trial [1]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the Biologics License Application (BLA) due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [1]. Group 2: Next Steps for Shareholders - Shareholders are advised to register for the class action by September 15, 2025, to participate in the case without any cost or obligation [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the lifecycle of the case [2]. Group 3: Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - The complaint against Fiserv alleges violations of federal securities laws due to misleading statements regarding the performance and growth of its Clover platform, particularly following the forced migration of Payeezy merchants [2]. Group 1: Allegations Against Fiserv - Fiserv allegedly forced Payeezy merchants to migrate to its Clover platform due to issues with the older Payeezy platform [2]. - The revenue growth and gross payment volume (GPV) of Clover were temporarily inflated by these forced conversions, masking a slowdown in new merchant business [2]. - A significant number of former Payeezy merchants reportedly switched to competitors due to Clover's high pricing and compatibility issues, leading to a slowdown in Clover's GPV growth [2]. Group 2: Market Reaction and Stock Performance - On April 24, 2025, Fiserv reported Clover GPV growth of only 8% for Q1 2025, a decline from 14-17% in 2024, resulting in an 18.5% drop in stock price to $176.90 [3]. - On May 15, 2025, Fiserv disclosed that GPV growth deceleration would persist throughout 2025, causing a further 16.2% decline in stock price to $159.13 [3]. - On July 23, 2025, Fiserv lowered its full-year organic growth guidance and reported a deceleration in quarterly organic revenue growth to 9% year-over-year, leading to a 13.9% drop in stock price to $143.00 [3].

Core Viewpoint - Lockheed Martin has faced significant financial losses due to internal control failures and operational challenges, leading to a series of negative announcements that have impacted its stock price and investor confidence [2][3][4]. Financial Performance - On October 22, 2024, Lockheed Martin announced a loss of $80 million related to a classified program, resulting in a 6.12% drop in share price to $576.98 [3][5]. - On January 28, 2025, the company reported pre-tax losses of $1.7 billion, with $555 million attributed to the Aeronautics program and $1.3 billion to the Missiles and Fire Control business, leading to a net earnings drop from $6.9 billion in 2023 to $5.3 billion in 2024 [4][5]. - On July 22, 2025, an additional $1.6 billion in pre-tax losses was disclosed, including $950 million from the Aeronautics Classified program, resulting in a further decline in net earnings to $342 million [6][7]. Stock Market Reaction - Following the October 2024 announcement, Lockheed Martin's share price fell by $37.63 [3][5]. - The January 2025 announcement led to a $46.24 drop in share price [4][5]. - The July 2025 announcement resulted in a $49.79 decline in share price [6][7]. Legal Implications - A class action lawsuit has been initiated against Lockheed Martin, alleging violations of federal securities laws due to misleading statements and failure to disclose critical operational issues [2][8]. - The lead plaintiff in the lawsuit is an investor with the largest financial interest in the case, representing the interests of the class [8]. Company Operations - The complaints highlight that Lockheed Martin lacked effective internal controls and procedures for accurate program reviews, which contributed to the financial losses [2]. - The company has faced challenges in delivering on contract commitments regarding cost, quality, and schedule, which has raised concerns about its operational integrity [2].

Core Viewpoint - Berger Montague PC is investigating potential securities law violations involving RxSight, Inc. following a class action lawsuit filed on behalf of investors who acquired RxSight securities during the specified Class Period [1][2]. Company Overview - RxSight, headquartered in Aliso Viejo, CA, is a medical technology company that develops light adjustable intraocular lenses (LAL) used in cataract surgery [2]. Legal Allegations - The lawsuit alleges that RxSight failed to disclose significant issues, including: 1. Adoption challenges and structural issues leading to declines in sales and utilization [3]. 2. Overstated demand for RxSight's products [3]. 3. Unlikelihood of meeting previously issued financial guidance for fiscal year 2025 [3]. Financial Impact - On July 8, 2025, RxSight reported significant declines in LDD sales, LAL utilization, and overall revenue for Q2 2025, subsequently lowering its full-year 2025 revenue guidance. CEO Ronald Kurtz attributed the decline to adoption challenges [4]. - Following this announcement, RxSight shares fell by $4.84, or 37%, closing at $7.95 per share on July 9, 2025 [4].

Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Sable Offshore Corp. (NYSE: SOC) who purchased shares during a specified class period, alleging that the company made materially false statements regarding its oil production activities [1][2]. Group 1: Allegations - The lawsuit claims that Sable Offshore Corp. falsely represented that it had restarted oil production off the coast of California when it had not, leading to misleading statements about the company's business and operations [2]. - The misleading information allegedly resulted in damages to investors when the true details became public [2]. Group 2: Class Action Details - The class period for the lawsuit is from May 19, 2025, to June 3, 2025, including a secondary public offering on May 21, 2025 [1]. - Shareholders are encouraged to register for the class action by September 26, 2025, to potentially be appointed as lead plaintiffs [3]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect the rights of investors who have suffered due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [4].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration of its business with 3M's Food Safety Division and the financial implications of this merger [1][3][4]. Company Overview - Neogen Corporation specializes in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. Class Action Details - The class action lawsuit is titled "Operating Engineers Construction Industry and Miscellaneous Pension Fund v. Neogen Corporation" and allows investors who purchased Neogen common stock between January 5, 2023, and June 3, 2025, to seek appointment as lead plaintiff by September 16, 2025 [1][7]. - The lawsuit alleges that Neogen's executives made false statements about the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3][4]. Financial Performance - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in fiscal year 2025 revenue and EBITDA guidance [4]. - In the third quarter of 2025, Neogen reported a loss of $11 million, a significant increase from a $2 million loss the previous year, with revenue declining by 3.4% to $221 million due to integration issues [5]. - On June 4, 2025, Neogen projected an EBITDA margin drop to the high teens from 22%, attributing this to elevated inventory write-offs, which led to a further decline in stock price by over 17% [6].

Core Viewpoint - Neogen Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the integration with 3M and the financial health of the company during the class period from January 5, 2023, to June 3, 2025 [1][3]. Company Overview - Neogen Corporation engages in the development, manufacture, and marketing of products and services focused on food and animal safety [2]. - The company announced a merger with the Food Safety Division of 3M in December 2021, which was completed in September 2022 [2]. Allegations of the Lawsuit - The lawsuit alleges that Neogen's executives misrepresented the progress of the integration with 3M and downplayed inefficiencies that arose during this process [3]. - On January 10, 2025, Neogen reported a significant GAAP net income loss due to a $461 million non-cash goodwill impairment charge related to the 3M acquisition, alongside a reduction in revenue and EBITDA guidance for fiscal year 2025 [4]. - Following the announcement of its third quarter results on April 9, 2025, Neogen reported a loss of $11 million, a revenue decline of 3.4% to $221 million, and a significant drop in stock price by 28% [5]. - On June 4, 2025, Neogen projected a drop in EBITDA margin to the high teens from 22%, leading to a further stock price decline of over 17% [6]. Legal Process - Investors who purchased Neogen common stock during the class period can seek appointment as lead plaintiff in the class action lawsuit, representing the interests of all class members [7]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [8][9].

Core Viewpoint - A class action has been filed against UroGen Pharma Ltd. for allegedly failing to conduct a proper trial for its lead drug candidate, UGN-102, which is intended to treat low-grade intermediate risk non-muscle invasive bladder cancer [1][2]. Group 1: Allegations and FDA Concerns - The complaint alleges that the FDA expressed doubts about the effectiveness of UGN-102 due to the lack of a concurrent control arm in the ENVISION clinical study, making the primary endpoints difficult to interpret [3]. - The FDA had recommended a randomized trial design multiple times during UroGen's product development, but the company chose not to follow this advice [3]. - Following the FDA's briefing document, UroGen's stock price fell by $2.54, or 25.8%, closing at $7.31 per share on May 16, 2025 [3]. Group 2: Advisory Committee Vote and Stock Impact - On May 21, 2025, the Oncological Drugs Advisory Committee voted against the approval of UGN-102, citing an unfavorable benefit-risk profile for patients [4]. - This negative vote led to a significant drop in UroGen's stock price, which fell by $3.37, or 44.7%, closing at $4.17 per share on the same day [4]. Group 3: Class Action Participation - Shareholders interested in participating in the class action must file their motion for lead plaintiff by July 28, 2025, with the lead plaintiff representing other class members in the litigation [6]. - Shareholders can choose to remain absent class members without participating in the case [6].

Core Viewpoint - Class actions have been initiated against Vestis Corporation, Reckitt Benckiser Group, and Tempus AI, highlighting significant legal challenges and potential financial implications for these companies [1][4][6]. Group 1: Vestis Corporation (NYSE: VSTS) - The class period for Vestis is from May 2, 2024, to May 6, 2025, with a lead plaintiff deadline of August 8, 2025 [2]. - The complaint alleges that Vestis made misleading statements about its business growth capabilities, particularly regarding customer retention and revenue generation [2]. - Following a disappointing financial report on May 7, 2025, Vestis' stock price plummeted from $8.71 to $5.44, a decline of approximately 37.54% in one day [3]. Group 2: Reckitt Benckiser Group plc (OTC: RBGLY) - The class period for Reckitt is from January 13, 2021, to July 28, 2024, with a lead plaintiff deadline of August 4, 2025 [4]. - Over 500 lawsuits have been filed against Reckitt, alleging failure to warn about the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious intestinal disease in premature infants [4][5]. - The allegations include misleading statements regarding the safety of Reckitt's products and the potential impact on sales and legal exposure [5]. Group 3: Tempus AI, Inc. (NASDAQ: TEM) - The class period for Tempus is from August 6, 2024, to May 27, 2025, with a lead plaintiff deadline of August 11, 2025 [6]. - The complaint claims that Tempus failed to disclose significant issues, including inflated contract values and questionable business practices that could jeopardize its financial stability [6]. - Following a critical report from Spruce Point Capital Management on May 28, 2025, Tempus' stock price fell from $65.87 to $53.20, a decrease of 19.23% [7][8].